Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.

Next Previous
X
Search
Trial Profile

A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above.

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AReSVi 006; RSV OA=ADJ-006
  • Sponsors GlaxoSmithKline Biologicals; GSK

    • Most Recent Events

    • 12 Sep 2024 This trial has been discontinued in Hungary, according to European Clinical Trials Database record.
    • 27 Aug 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
    • 15 Aug 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top